Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma

Cancer Biology and Therapy

Volumn 16, Issue 2, 2015, Pages 346-351

  Singh Kushwaha, Vandana ^a   Gupta, Seema ^a   Husain, Nuzhat ^b   Khan, Huma ^a   Negi, Mps ^c   Jamal, Naseem ^a   Ghatak, Ashim ^c  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b Ram Manohar Lohia Institute of Medial Sciences   (India)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Gefitinib; Head and neck; Methotrexate; Recurrent; Squamous cell carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEFITINIB; METHOTREXATE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BLEEDING; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; HEAD AND NECK NEOPLASMS; MIDDLE AGED; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; QUALITY OF LIFE; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84924598598     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/15384047.2014.961881     Document Type: Article

References (26)

1. Al-Sarraf M. Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control 2002; 9:387-99; PMID:12410178
2. Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F, Mittal BB, Pelzer H, Fung BB, Witt ME, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004; 15:1179; PMID:15277256; http://dx.doi.org/10.1093/annonc/mdh308
3. Brockstein BE. Management of recurrent head and neck cancer: recent progress and future directions. Drugs 2011; 71:1551-9; PMID:21861540; http://dx.doi.org/10.2165/11592540-000000000-00000
4. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992; 10:257-63; PMID:1732427
5. Forastiere AA, Mitch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: A Southwest Oncology Group Study. J Clin Oncol. 1992; 10:1241-51; PMID:1634913
6. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005; 23:8646-54; PMID:16314626; http://dx.doi.org/10.1200/JCO.2005.02.4646
7. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006; 24:2644-52; PMID:16763278; http://dx.doi.org/10.1200/JCO.2005.05.3348
8. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010; 21:252-61; PMID:20943624; http://dx.doi.org/10.1093/annonc/mdq453
9. Price KA, Cohen EE. Current Treatment Options for Metastatic Head and Neck Cancer. Curr Treat Options Oncol 2012; 13:35-46; PMID:22252884; http://dx.doi.org/10.1007/s11864-011-0176-y
10. Asaumi J, Nishijima K. Low dose sequential methotrexate and 5-fluorouracil administration is effective and safe as neo-adjuvant chemotherapy in oral cancer. In Vivo 1996; 10:559-62; PMID:8986464
11. Browman GP, Archibald SD, Young JE, Hryniuk WM, Russell R, Kiehl K, Levine MN. Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer. J Clin Oncol 1983; 1:787-92; PMID:6366132
12. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. U Clin Oncol 2006; 24:2666; PMID:16763281; http://dx.doi.org/10.1200/JCO.2005.04.8306
13. Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 2004; 58:959-65; PMID:14967456; http://dx.doi.org/10.1016/j.ijrobp.2003.07.010
14. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. Clin Oncol 2006; 24:4170-6; PMID:16943533; http://dx.doi.org/10.1200/JCO.2006.07.2587
15. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21:1980-7; PMID:12743152; http://dx.doi.org/10.1200/JCO.2003.10.051
16. Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11:8418-842; PMID:16322304; http://dx.doi.org/10.1158/1078-0432.CCR-05-1247
17. Kirby AM, A'Hern RP, D'Ambrosio C, Tanay M, Syrigos KN, Rogers SJ, Box C, Eccles SA, Nutting CM, Harrington KJ. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer. 2006; 94:631-6; PMID:16495923
18. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:1864-71; PMID:19289630; http://dx.doi.org/10.1200/JCO.2008.17.0530
19. Airoldi M, Pedani F, Brando V, Gabriele P, Orecchia R. Comparison of methotrexate and sequential methotrexate-5-fluorouracil for patients with recurrent squamous cell carcinoma of the oral cavity. Chemioterapia 1987; 6:390-2; PMID:3435920
20. Tortochaux J, Tao Y, Tournay E, Lapeyre M, Lesaunier F, Bardet E, Janot F, Lusinchi A, Benhamou E, Bontemps P, et al. Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent. Radiother Oncol 2011; 100:70-5; PMID:21741720; http://dx.doi.org/10.1016/j.radonc.2011.06.025
21. Schornagel JH, Verweij J, de Mulder PH, Lapeyre M, Lesaunier F, Bardet E, Janot F, Lusinchi A, Benhamou E, Bontemps P, et al. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J Clin Oncol 1995; 13:1649-55; PMID:7602354
22. Pitman SW, Kowal CD, Bertino JR. Methotrexate and 5-fluorouracil in sequence in squamous head and neck cancer. Semin Oncol 1983; 10:15-9; PMID:6346497
23. Ringborg U, Ewert G, Kinnman J, Lundqvist PG, Strander H. Sequential methotrexate-5-fluorouracil treatment of squamous cell carcinoma of the head and neck. Cancer 1983; 52:971-3; PMID:6603896; http://dx.doi.org/10.1002/1097-0142(19830915)52:6<971::AID-CNCR2820520606>3.0.CO;2-B
24. Rivera F, García-Castaño A, Vega N, Vega-Villegas ME, Gutiérrez-Sanz L. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther 2009; 9:1421-8; PMID:19828002; http://dx.doi.org/10.1586/era.09.113
25. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11:570-9; PMID:8445433
26. Shiraki M, Odajima T, Ikeda T, Sasaki A, Satoh M, Yamaguchi A, Noguchi M, Nagai I, Hiratsuka H. Combined expression of p53, cyclin D1 and epidermal growth factor receptor improves estimation of prognosis in curatively resected oral cancer. Mod Pathol 2005; 18:1482-9; PMID:16007067; http://dx.doi.org/10.1038/modpathol.3800455